Acorda Therapeutics, Inc. (Nasdaq: ACOR )
today announced that Michael Rogers, Chief Financial Officer will
present at the Credit Suisse 2014 Healthcare Conference in Phoenix on
Tuesday, November 11 at 3:30pm MT.
By Philip van Doorn, MarketWatch
"The largest and most persistent active investment opportunity is long-horizon mean reversion."
That statement may not be the easiest to understand, but it essentially means that separating your emotions from investment decisions can make you a lot of money.
GNCC Capital, Inc. (OTC:GNCP) (“The Company”) updates on its operations
and provides revenue guidance on its operations as follows:
Gold Coast Gaming Corp (“Gold Coast”) subsidiary Revenues (Actual):
August, 2014: Actual Gross Gaming - $664,510
September, 2014: Actual Gross Gaming - $830,203
October, 2014: Actual Gross Gaming - $1,027,255
Revenues and profits for both August and September, 2014 will be
accounted for in the Company’s financial year ended on September 30,
2014 as GNCC’s acquisition of Gold Coast was effective August 11, 2014.
Focus on the Completion of Phase 3 Clinical Trials and Commercial Preparations for Telotristat Etiprate in Carcinoid Syndrome Preparation for the Initiation of Phase 3 Development and Commercial Readiness for Sotagliflozin (LX4211) in Type 1 Diabetes
THE WOODLANDS, Texas , Nov.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.